Abstract
Objective: Treatment with immune checkpoint inhibitors (ICIs) is associated with unprecedented remission and long-term disease control. However, only a subset of gynecological cancer patients responds to current treatment with ICIs. The response of patients to ICIs has recently been linked to the formation of de novo lymphoid tissue in tumors, the so-called tertiary lymphoid structures (TLSs). My group identified a transcriptionally unique resident memory-like CD8 T cell subset that produces the lymphogenic chemokine CXCL13, an essential factor in lymphoid tissue formation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
